Celldex Therapeutics, Inc. Logo

Email this page: News Release

Interim Update from Randomized Phase 2 ReACT Study of Rindopepimut in Recurrent Bevacizumab-naive Glioblastoma Demonstrates Statistically Significant Survival Benefit


Separate multiple addresses with commas. Maximum 200 characters.

These email addresses will be used to email the page on your behalf and will not be used by Celldex Therapeutics, Inc. for any marketing purposes.


This helps Celldex Therapeutics, Inc. prevent automated submissions.